

Leyden Labs Acquires RIGImmune

Client News

September 9, 2026

Gunderson Dettmer represented RIGImmune in its acquisition by Leyden Labs.

RIGImmune is a biopharmaceutical company developing a new class of immune modulating therapies for diseases caused by RNA viruses and for antitumor immune response induction. Completed earlier this year, Leyden Labs' acquisition of RIGImmune added its RIG-101 and proprietary NEED™ (Nano-Emulsion Effective Delivery) intranasal delivery platform to the company's growing portfolio of airway-targeted medicines. The acquisition will support Leyden Labs' efforts to protect vulnerable populations from airborne viral infections.

The announcement of the acquisition comes as Leyden Labs reports positive Phase 1 results for RIG-101, an intranasal therapy initially being studied to prevent virus-triggered asthma exacerbations by strengthening natural antiviral defenses. In the recently completed trial, RIG-101 was shown to be safe and well tolerated in healthy volunteers and patients with asthma.

"These Phase 1 results provide encouraging evidence that RIG-101 has the profile needed to advance into Phase 2 patient studies," said Susan Sobolov, CTO of Leyden Labs and former President and COO of RIGImmune, [in the announcement of the acquisition](#). "We believe the enhancement of innate antiviral response represents a promising new therapeutic strategy for the prevention of a broad range of respiratory viral infections in vulnerable patients with chronic airway disease."

The Gunderson deal team was led by Tim Ehrlich and Tim Kulis and included Alex Bloom, Bennett Evans, Lily Kim, Ray Fang, Emily Cabrera, and Mark Macchi.

Related People

Timothy H. Ehrlich

PARTNER

P +1 617 648 9399

Timothy J. Kulis

PARTNER

P +1 617 648 9236

Alex Bloom

ASSOCIATE

P +1 617 648 9272

Bennett Evans

ASSOCIATE

P +1 617 648 9251

Lily H. Kim

PARTNER

P +1 650 463 5326

Ray Fang

ASSOCIATE

P +1 415 801 4855

Emily E. Cabrera

PARTNER

P +1 212 430 4201

Mark Macchi

ASSOCIATE

P +1 617 648 9383

Related Services

Life Sciences

Mergers & Acquisitions

Private & Public Companies

Featured Insights

PUBLIC VENTURES

Glass Lewis Invites Comment on Proposed 'Four Perspectives' Proxy Voting Research Model

FIRM NEWS

Gunderson Dettmer Commemorates 2026 Hispanic Heritage Month

CLIENT NEWS

Savvy Wealth Raises \$100 Million Series C

CLIENT NEWS

Bluecore Energy Announces \$50 Million Seed Financing

CLIENT NEWS

BrainChild Bio Closes \$116 Million Series A

CLIENT NEWS

Point72 Ventures and Spark Capital Co-Lead Stoke Space's \$1 Billion Series E

PUBLIC VENTURES

SEC Files Subpoena Enforcement Action Against ISS

CLIENT NEWS

Gunderson Dettmer Represents Addition and Lux Capital in Hugging Face Sale to NVIDIA for \$12.9 Billion

CLIENT NEWS

Harbert Growth Partners Leads Yardstik's \$30 Million Series B

FIRM NEWS

Massachusetts Lawyers Weekly Recognizes Gunderson Dettmer Partner Tim Ehrlich as a Go To Life Sciences Lawyer

CLIENT NEWS

Faro AI Announces \$37.3 Million Series B

CLIENT NEWS

Emerald AI Raises \$150 Million Series A at \$1.05 Billion Valuation